We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Ecolab posted 4% organic sales growth in Q1 2026, driven by pricing and volume gains.
ECL's Global High-Tech business grew more than 20% organically on semiconductor demand.
Ecolab Digital topped $400M in annualized revenue with AI and automation-driven solutions.
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a solid first-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist.
This Zacks Rank #3 (Hold) stock has lost 5.3% in the year-to-date period against the industry’s 7.7% growth. The S&P 500 Composite has increased 8.1% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $69.2 billion. It projects 14.3% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met once, delivering an average surprise of 0.23%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Strong Product Portfolio With a Focus on R&D: In first-quarter 2026, Ecolab’s organic sales rose 4%, driven by 3% pricing and 1% volume growth, reflecting the strong value proposition of its portfolio. Per management, the company continues to benefit from a robust innovation pipeline, with increasing focus on digitally enabled solutions that enhance customer productivity and sustainability.
Platforms like 3D TRASAR and other connected monitoring solutions are gaining traction by helping customers optimize water usage, energy consumption and operational efficiency. Management noted that these technology-driven offerings deliver measurable savings, strengthen long-term customer relationships and support premium pricing, reinforcing Ecolab’s competitive position across its end markets.
Ecolab’s Global High-Tech Business & Digital Platform: Per management, Ecolab’s Global High-Tech business remains a key long-term growth driver, supported by rising semiconductor manufacturing and data-center infrastructure investments worldwide. In first-quarter 2026, the segment delivered more than 20% organic sales growth, driven by new business wins across microelectronics and data centers. Management also noted that the Ovivo Electronics acquisition strengthens Ecolab’s ultrapure water capabilities for semiconductor fabs and, together with the pending CoolIT Systems acquisition, is expected to create a roughly $1.5 billion Global High-Tech platform.
Meanwhile, Ecolab Digital continues to scale as another important growth engine, with annualized revenues surpassing $400 million. Management highlighted that the platform leverages AI, predictive analytics, remote monitoring and automation to enhance customer productivity and sustainability outcomes, while addressing a $13 billion market opportunity, including nearly $3 billion within the existing customer base.
Strong Q1 Results: ECL exited the first quarter of 2026 with in-line earnings and better-than-expected revenues. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of the adjusted operating margin bodes well for the stock.
Per management, Ecolab’s performance in the reported quarter was driven by strong value pricing, accelerated volume growth and improved productivity, demonstrating the strength of its technology- and service-led model. Its core businesses also delivered strong performance as Institutional and Specialty both improved, and Food & Beverage continued to significantly outperform market trends. These looked promising for the stock.
A Factor That May Offset ECL’s Gains
Cost Fluctuations: Ecolab faces risks from raw material cost volatility, inflationary pressures and supply-chain disruptions, which could weigh on margins and profitability. Management expects commodity costs to rise at a high single-digit rate beginning in second-quarter 2026, primarily driven by energy-related expenses.
The company remains exposed to fluctuations in raw material availability and pricing, as well as challenges in renewing supply agreements on favorable terms, which could adversely impact operating results, financial position and cash flows. Additionally, geopolitical tensions and broader economic slowdowns may disrupt global sourcing and supplier performance, limiting Ecolab’s ability to secure raw materials efficiently and at competitive prices.
Estimate Trend
Ecolab is witnessing a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has moved south by 11 cents to $8.47 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $4.4 billion, indicating a 9.4% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Key Takeaways
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a solid first-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist.
This Zacks Rank #3 (Hold) stock has lost 5.3% in the year-to-date period against the industry’s 7.7% growth. The S&P 500 Composite has increased 8.1% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $69.2 billion. It projects 14.3% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met once, delivering an average surprise of 0.23%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Strong Product Portfolio With a Focus on R&D: In first-quarter 2026, Ecolab’s organic sales rose 4%, driven by 3% pricing and 1% volume growth, reflecting the strong value proposition of its portfolio. Per management, the company continues to benefit from a robust innovation pipeline, with increasing focus on digitally enabled solutions that enhance customer productivity and sustainability.
Platforms like 3D TRASAR and other connected monitoring solutions are gaining traction by helping customers optimize water usage, energy consumption and operational efficiency. Management noted that these technology-driven offerings deliver measurable savings, strengthen long-term customer relationships and support premium pricing, reinforcing Ecolab’s competitive position across its end markets.
Ecolab’s Global High-Tech Business & Digital Platform: Per management, Ecolab’s Global High-Tech business remains a key long-term growth driver, supported by rising semiconductor manufacturing and data-center infrastructure investments worldwide. In first-quarter 2026, the segment delivered more than 20% organic sales growth, driven by new business wins across microelectronics and data centers. Management also noted that the Ovivo Electronics acquisition strengthens Ecolab’s ultrapure water capabilities for semiconductor fabs and, together with the pending CoolIT Systems acquisition, is expected to create a roughly $1.5 billion Global High-Tech platform.
Meanwhile, Ecolab Digital continues to scale as another important growth engine, with annualized revenues surpassing $400 million. Management highlighted that the platform leverages AI, predictive analytics, remote monitoring and automation to enhance customer productivity and sustainability outcomes, while addressing a $13 billion market opportunity, including nearly $3 billion within the existing customer base.
Strong Q1 Results: ECL exited the first quarter of 2026 with in-line earnings and better-than-expected revenues. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of the adjusted operating margin bodes well for the stock.
Per management, Ecolab’s performance in the reported quarter was driven by strong value pricing, accelerated volume growth and improved productivity, demonstrating the strength of its technology- and service-led model. Its core businesses also delivered strong performance as Institutional and Specialty both improved, and Food & Beverage continued to significantly outperform market trends. These looked promising for the stock.
A Factor That May Offset ECL’s Gains
Cost Fluctuations: Ecolab faces risks from raw material cost volatility, inflationary pressures and supply-chain disruptions, which could weigh on margins and profitability. Management expects commodity costs to rise at a high single-digit rate beginning in second-quarter 2026, primarily driven by energy-related expenses.
The company remains exposed to fluctuations in raw material availability and pricing, as well as challenges in renewing supply agreements on favorable terms, which could adversely impact operating results, financial position and cash flows. Additionally, geopolitical tensions and broader economic slowdowns may disrupt global sourcing and supplier performance, limiting Ecolab’s ability to secure raw materials efficiently and at competitive prices.
Estimate Trend
Ecolab is witnessing a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has moved south by 11 cents to $8.47 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $4.4 billion, indicating a 9.4% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.